Tiziana Life Sciences Ltd (TLSA)


-0.01 (-1.62%)
Symbol TLSA
Price $0.7349
Beta 0.000
Volume Avg. 0.15M
Market Cap 73.923M
Shares () -
52 Week Range 0.5-1.39
1y Target Est -
DCF Unlevered TLSA DCF ->
DCF Levered TLSA LDCF ->
ROE -5.17% Neutral
ROA -5.60% Neutral
Operating Margin -
Debt / Equity 17.68% Neutral
P/E -4.90 Strong Sell
P/B 1.75 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest TLSA news

Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA
NASDAQ Global Market

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.